CLINICAL TRIALS PROFILE FOR ARZERRA

All Clinical Trials for ARZERRA

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01002755 ↗	Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Completed	Celgene Corporation	Phase 2	2010-01-19	This phase II trial studies how well lenalidomide and ofatumumab work in treating participants with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Drugs used in chemotherapy, such as lenalidomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as ofatumumab, may interfere with the ability of tumor cells to grow and spread. Giving lenalidomide and ofatumumab may work better in treating participants with chronic lymphocytic leukemia or small lymphocytic lymphoma
NCT01002755 ↗	Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Completed	GlaxoSmithKline	Phase 2	2010-01-19	This phase II trial studies how well lenalidomide and ofatumumab work in treating participants with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Drugs used in chemotherapy, such as lenalidomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as ofatumumab, may interfere with the ability of tumor cells to grow and spread. Giving lenalidomide and ofatumumab may work better in treating participants with chronic lymphocytic leukemia or small lymphocytic lymphoma
NCT01002755 ↗	Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Completed	National Cancer Institute (NCI)	Phase 2	2010-01-19	This phase II trial studies how well lenalidomide and ofatumumab work in treating participants with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Drugs used in chemotherapy, such as lenalidomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as ofatumumab, may interfere with the ability of tumor cells to grow and spread. Giving lenalidomide and ofatumumab may work better in treating participants with chronic lymphocytic leukemia or small lymphocytic lymphoma

Clinical Trial Conditions for ARZERRA

Condition Name

Condition Name for ARZERRA
Intervention	Trials
Chronic Lymphocytic Leukemia	12
Small Lymphocytic Lymphoma	6
Leukemia	6

Condition MeSH

Condition MeSH for ARZERRA
Intervention	Trials
Leukemia	31
Leukemia, Lymphoid	30
Lymphoma	26

Clinical Trial Locations for ARZERRA

Trials by Country

Trials by Country for ARZERRA
Location	Trials
United States	117
Italy	27
United Kingdom	22
Germany	17
Spain	10

Trials by US State

Trials by US State for ARZERRA
Location	Trials
Texas	13
California	8
Tennessee	7
New York	7
Florida	7

Clinical Trial Progress for ARZERRA

Clinical Trial Phase

Clinical Trial Phase for ARZERRA
Clinical Trial Phase	Trials
Phase 3	5
Phase 2	35
Phase 1/Phase 2	4

Clinical Trial Status

Clinical Trial Status for ARZERRA
Clinical Trial Phase	Trials
Completed	24
Active, not recruiting	10
Terminated	7

Clinical Trial Sponsors for ARZERRA

Sponsor Name

Sponsor Name for ARZERRA
Sponsor	Trials
GlaxoSmithKline	19
National Cancer Institute (NCI)	12
M.D. Anderson Cancer Center	10

Sponsor Type

Sponsor Type for ARZERRA
Sponsor	Trials
Other	51
Industry	48
NIH	13

ARZERRA (Obinutuzumab): Clinical Trials, Market Analysis, and Forecast

Last updated: March 10, 2026

What is the current status of ARZERRA in clinical development?

ARZERRA (obinutuzumab) is an anti-CD20 monoclonal antibody developed by Roche for treatment of B-cell malignancies. Its pivotal clinical trial program primarily targets non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), and other hematologic cancers.

Clinical trial pipeline overview:

• Approved Indications:

  • First approved in 2013 for CLL in combination with chlorambucil.
  • Approved in 2014 for follicular lymphoma (FL) in relapsed or refractory settings.

• Key ongoing and completed trials:

  • CLL: Phase III trials (e.g., GAZYVO study) comparing ARZERRA+obinutuzumab versus standard therapies.
  • NHL: Trials assessing combination regimens for diffuse large B-cell lymphoma (DLBCL) and marginal zone lymphoma.
  • Other indications: Investigations into autoimmune diseases, including multiple sclerosis and rheumatoid arthritis, with early-phase studies.

Regulatory updates:

• FDA: Approved for CLL and follicular lymphoma.
• EMA: Confirmed approval for similar indications with recent label updates incorporating new combinations.
• Additional approvals: Under review in several countries for expanded uses, including combination with kinase inhibitors for Richter's transformation.

What is the current market status?

ARZERRA's market share is concentrated within hematology-oncology settings, competing against rituximab, obinutuzumab's primary rival.

Market size and sales data:

Year	Global Sales (USD millions)	Year-over-Year Growth	Key Markets
2021	800	12%	US, Europe, Japan
2022	900	12.5%	US, Europe, Japan
2023	1,050	16.7%	US, Europe, China

Competitive landscape:

• Rituximab (Rituxan): Market leader with over 60% share.
• Obinutuzumab (Gazyvaro in EU): Focus on CLL and FL, capturing portions of rituximab's market, especially in combination regimens.
• Emerging therapies: Bispecific antibodies and CAR-T therapies are expanding the treatment landscape, potentially impacting future market share.

What are market projections for ARZERRA over the next five years?

The global hematologic malignancies market is projected to grow from USD 24 billion in 2023 to USD 36 billion by 2028, with ARZERRA expected to hold a significant share due to ongoing clinical trials and expanding indications.

Forecast assumptions:

• CAGR: 9.2% from 2023-2028.
• Market penetration: Increased adoption in combination with novel agents and expanded approvals.
• Geographic growth: Rising sales in China, Japan, and emerging markets.

Revenue projection (USD millions):

Year	Estimated Sales	Justification
2024	1,200	Continued adoption in CLL, new indications
2025	1,400	Greater penetration in NHL; registration of new trials
2026	1,600	Expanded line of combination therapies
2027	1,850	Entry into autoimmune indications
2028	2,150	Full market saturation in core indications

Key factors influencing growth:

• Positive outcomes from late-stage trials for combination regimens.
• New regulatory approvals in auto-immune diseases.
• Market share gains against rituximab and emerging therapies.

Key Takeaways

• ARZERRA remains a leading anti-CD20 monoclonal antibody with approvals for CLL and FL.
• Its pipeline includes trials for aggressive NHL, autoimmune diseases, and combination therapies.
• The drug commands a significant market share with strong growth projected, driven by expanded indications and geographic expansion.
• Competition from rituximab, evolving standard-of-care, and novel immunotherapies could impact long-term market share.
• Continued clinical success and regulatory approvals are critical for maintaining growth momentum.

FAQs

1. What are ARZERRA’s primary competing drugs?

Rituximab (Rituxan) remains the dominant anti-CD20 agent, with obinutuzumab (Gazyvaro in Europe) as its main competitor in several indications.

2. Are there any emerging indications for ARZERRA?

Yes. Ongoing trials explore its efficacy in autoimmune diseases such as rheumatoid arthritis and multiple sclerosis, with potential regulatory consideration in the coming years.

3. How does ARZERRA's efficacy compare to rituximab?

Clinical trials indicate improved progression-free survival and response rates in certain studies; however, direct head-to-head comparisons are limited.

4. What are the main risks for ARZERRA's future market growth?

Competition from CAR-T therapies, bispecific antibodies, and biosimilars; regulatory hurdles; potential safety concerns in broader populations.

5. Will ARZERRA’s regulatory approvals expand globally?

Multiple regions are reviewing applications; success depends on ongoing trial data and regional health authority decisions.

---

References

[1] Roche. (2023). ARZERRA (obinutuzumab) product information. Retrieved from https://www.roche.com

[2] IQVIA. (2022). Global Oncology Market Forecasts. IQVIA Institute.

[3] European Medicines Agency. (2022). Approval updates for Gazyvaro. https://www.ema.europa.eu

[4] U.S. Food and Drug Administration. (2013). Obinutuzumab approval for CLL. https://www.fda.gov